Removal and inactivation of viruses during the manufacture of a high-purity antihemophilic factor IX from human plasma

Biotechnology and Bioprocess Engineering

Volumn 14, Issue 6, 2009, Pages 716-724

  Kim, In Seop ^a   Bae, Jung Eun ^a   Sung, Hark Mo ^a,b   Kang, Yong ^b   Choi, Yong Woon ^b,c  

^a Hannam University   (South Korea)

^b Green Cross Company   (South Korea)

^c Ajou University   (South Korea)

Author keywords

Antihemophilic factor IX; Log reduction factor; Viral inactivation and or removal; Virus safety

Indexed keywords

AFFINITY COLUMN; ANION-EXCHANGE COLUMN CHROMATOGRAPHY; BLOOD-BORNE VIRUS; DEAE-TOYOPEARL 650M; ENVELOPED VIRUS; EXPERIMENTAL MODELS; HEPATITIS A VIRUS; HIGH-PURITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PLASMAS; LOG REDUCTION FACTOR; LOG REDUCTIONS; PATHOGENIC VIRUS; PRODUCTION PROCESS; REDUCTION CAPACITY; REDUCTION FACTOR; SCALE-DOWN; TWEEN 80; VIRAL INACTIVATION; VIRAL INACTIVATION AND/OR REMOVAL;

CHROMATOGRAPHIC ANALYSIS; COLUMN CHROMATOGRAPHY; GEL PERMEATION CHROMATOGRAPHY; MANUFACTURE; ORGANIC SOLVENTS; PLASMA (HUMAN); POLYSACCHARIDES; PRODUCTION ENGINEERING; SAFETY FACTOR; TISSUE CULTURE; TRICHLOROETHYLENE;

VIRUSES;

2 DIETHYLAMINOETHANOL; BLOOD CLOTTING FACTOR 9; DETERGENT; GREENNINE VF; HEPARIN; ORGANIC SOLVENT; POLYSORBATE 80; SEPHAROSE; TRIBUTYL PHOSPHATE; UNCLASSIFIED DRUG;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BOVINE DIARRHEA VIRUS; BOVINE HERPES VIRUS; CALCULATION; CONTROLLED STUDY; DRUG PURIFICATION; DRUG PURITY; HEPATITIS A VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PLASMA; VIRUS INACTIVATION; VIRUS TITRATION;

BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1; ENCEPHALOMYOCARDITIS VIRUS; HEPATITIS A VIRUS; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; MURINAE; PORCINE PARVOVIRUS;

EID: 77149171444     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12257-009-0167-z     Document Type: Article

References (47)

1. N. M. O'Connell 2003 Factor XI deficiency-from molecular genetics to clinical management Blood Coagul. Fibrinolysis 14 59 64 10.1097/00001721- 200306001-00014 (Pubitemid 36951886)
2. S. A. Berkman 1988 Infectious complications of blood transfusion Blood Rev. 2 206 210 10.1016/0268-960X(88)90026-4 1:STN:280:DyaL1M%2FislaksQ%3D%3D (Pubitemid 18227912)
3. A. Gröner 2008 Pathogen safety of plasma-derived products - Haemate P/Humate-P Haemophilia 14 54 71 10.1111/j.1365-2516.2008.01852.x
4. J. W. Mosley J. Rakela 1999 Foundling viruses and transfusion medicine Transfusion 39 1041 1044 10.1046/j.1537-2995.1999.39101041.x 1:STN:280:DC%2BD3c%2FgtVeqtw%3D%3D (Pubitemid 29485317)
5. L. G. Guertler 2002 Virus safety of human blood, plasma, and derived products Thromb. Res. 107 S39 S45 10.1016/S0049-3848(02)00151-2 1:CAS:528:DC%2BD38XnvVGqtbg%3D
6. H. G. Klein 2005 Pathogen inactivation technology: cleansing the blood supply J. Intern. Med. 257 224 237 10.1111/j.1365-2796.2005.01451.x 1:STN:280:DC%2BD2M%2Fos1Omuw%3D%3D (Pubitemid 40342125)
7. E. Tabor 1999 The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1 Transfusion 39 1160 1168 10.1046/j.1537-2995.1999. 39111160.x 1:STN:280:DC%2BD3c%2FmslOgsg%3D%3D
8. B. J. Bryant H. G. Klein 2007 Pathogen inactivation: the definitive safeguard for the blood supply Arch. Pathol. Lab. Med. 131 719 733 1:CAS:528:DC%2BD2sXmtFehu7c%3D
9. B. H. Robertson D. D. Erdman 2000 Nonenveloped viruses transmitted by blood and blood products Dev. Biol. Stand. 102 29 35 1:STN:280: DC%2BD3c3lt1SlsA%3D%3D
10. R. Laub P. Strengers 2002 Parvovirus and blood products Pathol. Biol. (Paris) 50 339 348 1:CAS:528:DC%2BD38XktFKntLo%3D
11. T. Burnouf M. Radosevich 2000 Reducing the risk of infection from plasma products: specific preventative strategies Blood Rev. 14 94 110 10.1054/blre.2000.0129 1:STN:280:DC%2BD3cvlsFSkuw%3D%3D (Pubitemid 30616183)
12. J. J. Morgenthaler 2000 New development in plasma fractionation and virus inactivation Vox Sang 78 217 221 10.1046/j.1423-0410.2000.7840217.x
13. J. S. Powell M. Bush J. Harrison C. Abildgaard E. Vosburgh A. R. Thompson D. Hurst 2000 Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A Haemophilia 6 140 149 10.1046/j.1365-2516.2000.00407.x 1:STN:280:DC%2BD3c3ltlGrsw%3D%3D (Pubitemid 30312466)
14. S. Chandra A. Groener F. Feldman 2002 Effectiveness of alternative treatment for reducing potential viral contaminants from plasma-derived products Thromb. Res. 105 391 400 10.1016/S0049-3848(02)00044-0 1:CAS:528: DC%2BD38XksVagsL4%3D (Pubitemid 34621256)
15. J. S. Shin Y. W. Choi H. M. Sung Y. W. Ryu I. S. Kim 2006 Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment Biotechnol. Bioprocess Eng. 11 19 25 10.1007/BF02931863 1:CAS:528:DC%2BD28Xit1Kgu7c%3D
16. I. S. Kim Y. W. Choi Y. Kang H. M. Sung J. S. Shin 2008 Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma J. Microbiol. Biotechnol. 18 997 1003 1:CAS:528:DC%2BD1MXotFSlsrw%3D
17. S. M. Robinson H. Schwinn A. Smith 1992 Clotting factors and hepatitis A Lancet 340 1465 10.1016/0140-6736(92)92652-V 1:STN:280:DyaK3s%2Fos1answ%3D%3D
18. E. Lawlor S. Graham E. Davidson P. L. Yap C. Cunningham H. Daly I. J. Temperley 1996 Hepatitis A transmission by factor IX concentrates Vox Sang 73 189 190
19. M. Chudy I. Budek B. Keller-Stanislawski K. A. McCaustland S. Neidhold B. H. Robertson C. M. Nubling R. Seitz J. Lower 1999 A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool J. Med. Virol. 57 91 99 10.1002/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L 1:STN:280:DyaK1M7gslCjug%3D%3D (Pubitemid 29022497)
20. S. A. Limentani K. P. Gowell S. R. Deitcher 1995 High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential Acta Haematol. 94 12 17 10.1159/000204023 1:CAS:528:DyaK2MXpslWns7g%3D
21. M. Köhler P. Hellstern E. Lechler P. Überfuhr G. Müller-Berghaus 1998 Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates Thromb. Haemost. 80 399 402
22. Y. Kang Y. W. Choi M. S. Hark K. W. Sohn J. S. Shin I. S. Kim 2008 Industrial-scale production of high-purity antihemophilic factor IX from human plasma Korean J. Biotechnol. Bioeng. 23 37 43
23. I. S. Kim Y. W. Choi Y. Kang H. M. Sung K. W. Sohn Y.-S. Kim 2008 Improvement of virus safety of an antihemophilic factor IX by virus filtration process J. Micobiol. Biotechnol. 18 1317 1325 1:CAS:528:DC%2BD1MXotFSmtr8%3D
24. I. S. Kim Y. W. Choi S. R. Lee 2004 Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine J. Microbiol. Biotechnol. 14 140 147 1:CAS:528:DC%2BD2cXislalsrg%3D
25. G. R. Bolton S. Spector D. LaCasse 2006 Increasing the capacity of parvovirus-retentive membranes: performance of the ViresolveTM prefilter Biotechnol. Appl. Biochem. 43 55 63 10.1042/BA20050108 1:CAS:528: DC%2BD28Xms1CitA%3D%3D (Pubitemid 43059040)
26. B. Trijzelaar 1993 Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice-validation of virus removal and inactivation Biotherapy 6 93 102 10.1007/BF01877422 1:STN:280: DyaK2c%2FgtFehuw%3D%3D
27. P. Celis G. Silvester 2004 European regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies, and plasma derived medicinal products Dev. Biol. (Basel) 118 3 10 1:STN:280:DC%2BD2M%2FhvFCjsA%3D%3D
28. M. Farshid 2004 Viral safety evaluation of plasma-derived therapeutic products Dev. Biol. 118 11 15 1:STN:280:DC%2BD2M%2FhvFCjsQ%3D%3D
29. Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit (1996) Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95).
30. International Conference on Harmonisation 1998 Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability Federal. Resister 63 51074 51084
31. I. S. Kim H. G. Eo C. W. Park C. E. Chang S. Lee 2001 Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma Biotechnol. Bioprocess Eng. 6 25 30 10.1007/BF02942246 1:CAS:528:DC%2BD3MXhs12ksL4%3D
32. Y. W. Choi I. S. Kim 2008 Viral clearance during the manufacture of urokinase from human urine Biotechnol. Bioprocess. Eng. 13 25 32 10.1007/s12257-007-0140-7 1:CAS:528:DC%2BD1cXjtVejtrY%3D (Pubitemid 351356223)
33. J. Kärber 1931 Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche Arch. Exp. Path. Pharmak. 162 480 483 10.1007/BF01863914
34. A. Aghaie A. A. Pourfatollah S. Z. Bathaie S. M. Moazzeni M. P. H. Khorsand Z. Sharifi 2008 Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization Hum. Antibodies 17 79 84 1:CAS:528:DC%2BD1cXhtlyjtL7P
35. P. L. Roberts D. Lloyd P. J. Marshall 2009 Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20 Biologicals 37 26 31 10.1016/j.biologicals.2008.08.003 1:CAS:528:DC%2BD1MXntVCnsw%3D%3D
36. M. S. Horowitz C. Rooks B. Horowitz M. W. Hilgartner 1986 Virus safety of solvent/detergent treated antihaemophiliac factor concentrates Lancet 2 186 189
37. A. M. Prince B. Horowitz B. Brotman 1986 Sterilization of hepatitis and HTLV III viruses by exposure to Tri-(n-Butyl) phosphate and sodium cholate Lancet 1 706 710 10.1016/S0140-6736(86)91101-3 1:CAS:528:DyaL28XitFejtbs%3D
38. B. Horowitz A. Lazo H. Grossberg G. Page A. Lippin G. Swan 1998 Virus inactivation by solvent/detergent treatment and the manufacture of SDplasma Vox Sang 74 203 206 1:CAS:528:DyaK1cXkvFCitr4%3D
39. P. M. Mannucci 1993 Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates Vox Sang 64 197 203 10.1111/j.1423-0410.1993. tb03055.x 1:STN:280:DyaK3s3pslWmtw%3D%3D
40. I. S. Kim Y. W. Choi H. S. Woo C. E. Chang S. Lee 2000 Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate J. Microbiol. 38 187 191 1:CAS:528:DC%2BD3cXnsF2gt7g%3D
41. D. Josić P. Schulz L. Biesert L. Hoffer H. Schwinn M. Kordis-Krapez A. Strancar 1997 Issues in the development of medical products based on human plasma J. Chromatogr. B: Biomed. Sci. Appl. 694 253 269 10.1016/S0378-4347(97)00130-8 (Pubitemid 27289498)
42. H. Arahana 2001 Viral clearance strategies for biopharmaceutical safety. Part 1: General considerations Bio. Pharm. 14 28 35
43. A. Darling 2002 Validation of biopharmaceutical purification processes for virus clearance evaluation Mol. Biotechnol. 21 57 83 10.1385/MB:21:1:057 1:CAS:528:DC%2BD38Xjt1ers7c%3D
44. K. Brorson J. Brown E. Hamilton K. E. Stein 2003 Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use J. Chromatogr. A. 989 155 163 10.1016/S0021-9673(02)01697-7 1:CAS:528:DC%2BD3sXht1Ghtb4%3D (Pubitemid 36197823)
45. Arahana, H. (2001) Viral clearance strategies for biopharmaceutical safety. Part 2: filtration for viral clearance. Bio. Pharm. February: 32-43.
46. S. Schmidt J. Mora S. Dolan J. Kauling 2005 An integrated concept for robust and efficient virus clearance and contaminant removal in biotech processes BioProcess Int. 3 26 31
47. I. S. Kim Y. W. Choi S. R. Lee Y. Kang K. M. Lee D. H. Park H. S. Woo S. Lee 2002 Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine Biotechnol. Bioprocess Eng. 7 340 346 10.1007/BF02933518 1:CAS:528:DC%2BD3sXislGjtA%3D%3D